Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients

NCT01622933 is registered in ClinicalTrials.gov with Lisa H. Butterfield, Ph.D. as lead sponsor.

NCT NCT01622933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01622933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Lead sponsor
Lisa H. Butterfield, Ph.D.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
August 31, 2017
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma